New combo therapy targets tough lung cancer in early trial

NCT ID NCT07325136

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests an experimental drug called BMS-986525, given alone or with the immunotherapy nivolumab (Opdivo), in 240 people whose small cell lung cancer has returned or stopped responding to standard platinum-based chemotherapy. The main goals are to check safety and tolerability, and to see if the drug shrinks tumors. The trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986525 (an experimental drug) and nivolumab (Opdivo, an immunotherapy)
What this could lead to: If successful, this could provide a new treatment option for people with relapsed/refractory small cell lung cancer, potentially improving tumor shrinkage or slowing disease progression.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. The experimental drug may cause side effects or fail to work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY SMALL CELL LUNG CANCER

Contacts and locations

Locations

Duke Cancer Institute
RECRUITING

Durham, North Carolina, 27710, United States
Istituto Clinico Humanitas
RECRUITING

Rozzano, Milano, 20089, Italy
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Local Institution - 0003
NOT_YET_RECRUITING

Craiova, 200347, Romania
Local Institution - 0009
NOT_YET_RECRUITING

Madrid, 28041, Spain
Local Institution - 0018
NOT_YET_RECRUITING

Chuo-ku, Tokyo, 104-0045, Japan
Local Institution - 0020
NOT_YET_RECRUITING

Hirakata, Osaka, 573-1191, Japan
Local Institution - 0026
NOT_YET_RECRUITING

Buffalo, New York, 14263, United States
Local Institution - 0028
NOT_YET_RECRUITING

Shanghai Shi, Shanghai Municipality, 200120, China
Oncohelp Medical Center
RECRUITING

Timișoara, Timiș County, 300239, Romania
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.